查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627626

全球免疫抑制劑市場：預測（2025-2030）

Global Immunosuppressant Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球免疫抑制劑市場規模預計將以12.42%的複合年成長率成長，從2025年的427.21億美元增至2030年的767.19億美元。

免疫抑制劑在臨床上可用於治療皮膚病、多發性硬化症和類風濕性關節炎等自體免疫疾病。這些藥物也稱為抗排斥藥物，可防止移植器官出現排斥反應。幫助患有慢性疾病的人，特別是那些需要器官移植的人的需要，以及增強移植過程的技術進步可能會顯著促進市場成長。

根據世界衛生組織 (WHO) 2023 年 9 月的報告，非傳染性疾病 (NCD) 每年導致約 4,100 萬人死亡，約佔全球死亡人數的 74%。這些疾病包括呼吸系統疾病、癌症、腎臟疾病和心血管疾病。免疫抑制劑的開發和器官移植的進步預計將減少這些疾病造成的死亡並擴大市場。

免疫抑制劑市場的促進因素

  • 慢性病的增加促進了免疫抑制劑市場的成長

由於急性白血病、難治性貧血和骨質疏鬆症，對幹細胞移植的需求不斷增加，而導致腎臟移植的慢性腎臟病也在增加。因此，器官移植的負擔導致免疫抑制藥物的需求大幅上升，進一步拉動全球市場。臨床試驗的擴大、併購的增加以及支持藥物發現和藥物開發的CDMO和CRO的快速成長也是推動市場擴張的因素。

免疫抑制劑市場的地理前景

  • 預計北美在預測期內將出現顯著成長

技術進步和市場參與企業的存在正在推動該區域市場的發展。在美國和加拿大等國家，器官移植和相關手術的需求不斷增加，免疫抑制劑的需求不斷增加，支持了市場的擴張。大眾對器官捐贈的認知不斷提高，也為更多的移植手術打開了大門，並可能在未來五年加速免疫抑制劑市場的成長。在美國，90%的成年人支持器官捐贈。由於該地區自體免疫疾病盛行率上升以及研發成本上升，免疫抑制劑市場正在擴大。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋關鍵和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中發現新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業與市場考量、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022年至2030年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 區域收益成長和預測分析，包括細分市場和國家
  • 公司簡介（主要是策略、產品、財務資訊、主要動態等）

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球免疫抑制劑市場：依藥物類別

  • 介紹
  • Calcineurin抑制劑
  • mTOR抑制劑
  • 抗體
  • 其他

第6章全球免疫抑制劑市場：依應用分類

  • 介紹
  • 器官移植
  • 自體免疫疾病

第7章全球免疫抑制劑市場：依通路分類

  • 介紹
  • 線上
  • 離線

第8章全球免疫抑制劑市場：按地區

  • 介紹
  • 北美洲
    • 按藥品類別
    • 按用途
    • 按分銷管道
    • 按國家/地區
  • 南美洲
    • 按藥品類別
    • 按用途
    • 按分銷管道
    • 按國家/地區
  • 歐洲
    • 按藥品類別
    • 按用途
    • 按分銷管道
    • 按國家/地區
  • 中東/非洲
    • 按藥品類別
    • 按用途
    • 按分銷管道
    • 按國家/地區
  • 亞太地區
    • 按藥品類別
    • 按用途
    • 按分銷管道
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 併購/協議/合作
  • 競爭對手儀表板

第10章 公司簡介

  • Astellas Pharma Inc.
  • Sanofi
  • AbbVie Inc.
  • Veloxis Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin
  • Neovii
  • F. Hoffmann-La Roche Ltd
  • Biocon
  • Novartis
  • Pfizer
  • Veloxis
簡介目錄
Product Code: KSI061613971

The global Immunosuppressant Drugs market is expected to grow at a CAGR of 12.42%, reaching a market size of US$76.719 billion in 2030 from US$42.721 billion in 2025.

Immunosuppressive drugs find their clinical utility in managing autoimmune diseases such as skin disorders, multiple sclerosis, and rheumatoid arthritis. These medications, which are also known as anti-rejection medications, prevent our body from rejecting transplanted organs. The need to support populations with chronic ailments, particularly those requiring organ transplants and technological advancements that enhance the transplant process, would significantly increase market growth.

According to the World Health Organization report in September 2023, about 41 million die per year from noncommunicable diseases (NCDs), which equals about 74% of all deaths in the world. It would cover respiratory, cancer, kidney, cardiovascular diseases, etc. Improving immunosuppressive medications and the development of organ transplantation would hence reduce some of the mortalities caused by these diseases and boost market expansion.

Global Immunosuppressant Drugs Market Drivers

  • Rising chronic health diseases are contributing to the global Immunosuppressant Drugs market growth

Stem cell transplant requirements are rising for acute leukemia, refractory anemia, and osteopetrosis, while there is an increase in chronic renal diseases that cause kidney transplants. The organ transplant burden has thus led to a colossal rise in the demand for immunosuppressants and has further contributed to the global market. Increasing clinical trials, growing mergers and acquisitions, and the fast-growing CDMOs and CROs supporting drug discovery and development are additional factors fostering market expansion.

Global Immunosuppressant Drugs Market Geographical Outlook

  • North America is witnessing exponential growth during the forecast period.

Technological advancements and the presence of significant market participants aid the development of this regional market. In nations like the US and Canada, rising demand for organ transplants and related procedures increases demand for immunosuppressive medications, propelling market expansion. Growing public awareness of organ donation is also opening the door for more transplant procedures, which will accelerate the immunosuppressive medication market's growth over the next five years. In the United States, 90% of adults favor organ donation. The market for immunosuppressive medications is expanding due to the region's increasing prevalence of autoimmune disease and R&D spending.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The global Immunosuppressant Drugs market is segmented and analyzed as follows:

By Drug Class

  • Calcineurin Inhibitors
  • mTOR inhibitor
  • Antibodies
  • Others

By Application

  • Organ Transplantation
  • Autoimmune Disorder

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Calcineurin Inhibitors
  • 5.3. mTOR inhibitor
  • 5.4. Antibodies
  • 5.5. Others

6. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Organ Transplantation
  • 6.3. Autoimmune Disorder

7. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Online
  • 7.3. Offline

8. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Application
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Application
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Italy
      • 8.4.4.5. Spain
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Application
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Application
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Astellas Pharma Inc.
  • 10.2. Sanofi
  • 10.3. AbbVie Inc.
  • 10.4. Veloxis Pharmaceuticals Inc.
  • 10.5. GlaxoSmithKline plc
  • 10.6. Dr. Reddy's Laboratories Ltd.
  • 10.7. Lupin
  • 10.8. Neovii
  • 10.9. F. Hoffmann-La Roche Ltd
  • 10.10. Biocon
  • 10.11. Novartis
  • 10.12. Pfizer
  • 10.13. Veloxis